Fig. 6

The mechanism of Niraparib in upregulating the proportion and function of T cells. A Western blot (WB) analysis of the STING pathway in SKOV3 and UWB1.289 cancer cells treated with different concentrations of Niraparib. B Quantification of data from the control and Niraparib treatment (15 µM) group. C, D Enzyme-linked immunosorbent assay (ELISA) analysis of the Interferon β (IFN-β) levels, chemokine (C–C motif) ligand 5 (CCL5) and, C-X-C motif chemokine 10 (CXCL10) from a co-culture system treated with control, Niraparib. E, F The cGAS/STING pathway was inhibited by H-151. The PD-L1, CCL5, and CXCL10 expression were analyzed by WB and ELISA after Niraparib treatment. All experiments were repeated three times. Data are presented as the mean ± SD. *P < 0.05, **P < 0.01